A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)

BACKGROUND: Approved first-line treatments for patients with BRAF V600–mutant advanced melanoma include nivolumab (a programmed cell death protein 1 inhibitor) plus ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor; NIVO+IPI) and the BRAF/MEK inhibitors dabrafenib plus trametinib (DAB+TRAM),...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarhini, A.A., Toor, K., Chan, K., McDermott, D.F., Mohr, P., Larkin, J., Hodi, F.S., Lee, C.-H., Rizzo, J.I., Johnson, H., Moshyk, A., Rao, S., Kotapati, S., Atkins, M.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872980/
https://www.ncbi.nlm.nih.gov/pubmed/33556898
http://dx.doi.org/10.1016/j.esmoop.2021.100050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872980/
https://www.ncbi.nlm.nih.gov/pubmed/33556898
http://dx.doi.org/10.1016/j.esmoop.2021.100050

Ejemplares similares